I used to have a claw hand at all times, and contort my limbs in weird positions at night (causing pain during the daytime) as well. I used braces for a couple of years. LDN has mostly taken care of that for me, except when I had one flare.

The American Academy of Neurology is having their Annual Meeting on Apr 123 - 19th, and the results from the LDN trials will be presented. Perhaps your doc might be more convinced then:
______________________

[P02.151] A Single Center, Randomized, Placebo-Controlled, Double-Crossover Study of the Effects of Low Dose Naltrexone on Multiple Sclerosis Quality of Life

Bruce Cree, Michael Ross, Ivo Violich, Brendan Berry, Azadeh Beheshtian, Elena Kornyeyeva, Douglas Goodin, San Francisco, CA

OBJECTIVE: To assess the efficacy of low dose naltrexone (LDN, 4.5mg) versus placebo on the Multiple Sclerosis Quality of Life Inventory (MSQOL54) and visual analog scale (VAS) in subjects with multiple sclerosis (MS). BACKGROUND: Anecdotal reports from some MS patients suggest that LDN may improve their quality of life. There are no published studies of LDN in MS. DESIGN/METHODS: This is a single-center, randomized, double-masked, placebo-control, cross-over trial to assess the efficacy LDN on MS patients quality of life. Subjects with MS between 18 and 75 years of age, taking glatiramer acetate, interferon beta, or no disease modifying treatment were enrolled in the study. Subjects were randomized to either 4.5 mg LDN or placebo nightly for 8 weeks. Following a one week wash out, subjects were switched to the alternate study drug for an additional 8 weeks. All subjects were evaluated using the MSQOL54 questionnaire and VAS at baseline and at weeks 8 and 17. RESULTS: 89 patients were randomized. 57 women with mean age of 49.1 years and 32 men with mean age of 47.8 years participated. 49 relapsing remitting, 16 secondary progressive, 23 primary progressive, and 1 progressive relapsing MS subjects enrolled. 16 subjects were on glatiramer acetate, 23 on interferon beta and 50 subjects were not on disease modifying therapies. 73 patients will complete the study by November 8th, 2007. 15 subjects voluntarily withdrew. 1 subject withdrew due to an unrelated medical condition. No subjects were withdrawn due to adverse events attributable to study drug. The efficacy of LDN versus placebo on the subscales of the MSQOL54 and the VAS will be presented. In addition, interactions between LDN and interferon beta or glatiramer acetate will be assessed. CONCLUSIONS/RELEVANCE: This study will establish LDNs safety and efficacy on MS quality of life. Supported by: Gifts from private donors.
Category - MS and Related Diseases
SubCategory - Clinical Science

Tuesday, April 15, 2008 11:30 AM

Poster Sessions II: Multiple Sclerosis and Related Diseases: Therapeutics (11:30 AM-2:30 PM)
_________________________________

[P02.151] A Single Center, Randomized, Placebo-Controlled, Double-Crossover Study of the Effects of Low Dose Naltrexone on Multiple Sclerosis Quality of Life

Bruce Cree, Michael Ross, Ivo Violich, Brendan Berry, Azadeh Beheshtian, Elena Kornyeyeva, Douglas Goodin, San Francisco, CA

OBJECTIVE: To assess the efficacy of low dose naltrexone (LDN, 4.5mg) versus placebo on the Multiple Sclerosis Quality of Life Inventory (MSQOL54) and visual analog scale (VAS) in subjects with multiple sclerosis (MS). BACKGROUND: Anecdotal reports from some MS patients suggest that LDN may improve their quality of life. There are no published studies of LDN in MS. DESIGN/METHODS: This is a single-center, randomized, double-masked, placebo-control, cross-over trial to assess the efficacy LDN on MS patients quality of life. Subjects with MS between 18 and 75 years of age, taking glatiramer acetate, interferon beta, or no disease modifying treatment were enrolled in the study. Subjects were randomized to either 4.5 mg LDN or placebo nightly for 8 weeks. Following a one week wash out, subjects were switched to the alternate study drug for an additional 8 weeks. All subjects were evaluated using the MSQOL54 questionnaire and VAS at baseline and at weeks 8 and 17. RESULTS: 89 patients were randomized. 57 women with mean age of 49.1 years and 32 men with mean age of 47.8 years participated. 49 relapsing remitting, 16 secondary progressive, 23 primary progressive, and 1 progressive relapsing MS subjects enrolled. 16 subjects were on glatiramer acetate, 23 on interferon beta and 50 subjects were not on disease modifying therapies. 73 patients will complete the study by November 8th, 2007. 15 subjects voluntarily withdrew. 1 subject withdrew due to an unrelated medical condition. No subjects were withdrawn due to adverse events attributable to study drug. The efficacy of LDN versus placebo on the subscales of the MSQOL54 and the VAS will be presented. In addition, interactions between LDN and interferon beta or glatiramer acetate will be assessed. CONCLUSIONS/RELEVANCE: This study will establish LDNs safety and efficacy on MS quality of life. Supported by: Gifts from private donors.
Category - MS and Related Diseases
SubCategory - Clinical Science

Tuesday, April 15, 2008 11:30 AM

Poster Sessions II: Multiple Sclerosis and Related Diseases: Therapeutics (11:30 AM-2:30 PM)
________________________

http://www.abstracts2view.com/aan200...04-15&expand=1

There are MANY doctors, neuros, MS specialists, MS Clinics and research centers that are rxing LDN now . . .

Cherie